Utilizing Ligand Binding Assays (LBA) and Critical Reagents for Drug Development

Critical reagents – the key components used in LBA – are central to ensuring the consistency and reliability of the assay and can often slow the progress of LBA due to limited availability. In this panel discussion, we examine the current scope of LBAs, the advantages and limitations including matrix interference, as well as the solutions for overcoming these. Additionally, we explore the platforms currently used and the key factors to consider when choosing a platform. Finally, we will highlight key areas for progression.

"*" indicates required fields

Name

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*